HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ultragen’s Stop device

This article was originally published in The Rose Sheet

Executive Summary

Ultragen is launching skin-renewal device Stop in France after partnering with French equipment supplier Logicom, according to Sept. 2 release. Hand-held Stop device offers consumers the opportunity to enjoy at home the aesthetic benefits of focused TriPollar radiofrequency originally developed for use exclusively in professional settings. According to Dr. Zion Azar, founder of Ultragen and creator of TriPollar, "Logicom has already secured a seven-figure order for the Stop, and we look forward to developing business in [France] further." Logicom will be responsible for overseeing retail partners and building long-term business relationships, Ultragen notes. Stop device, touted as an alternative to invasive surgical techniques for skin tightening, firming and renewal, is slated to launch in upscale UK department stores later this year (1"The Rose Sheet," Sept. 1, 2008, p. 9)

You may also be interested in...



Consumers Seeking RF Skin Renewal Can Stop Going To Clinic, Stay At Home

Ultragen Ltd. enters the growing market for home-use aesthetic devices with its hand-held Stop skin renewal device, which uses TriPollar radiofrequency technology to reduce visible signs of aging, the company says

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS015652

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel